
Helping people build families and live better lives through innovative biopharmaceuticals.
Ferring acquired Rebiotix and markets RBX2660, an approved live biotherapeutic for C. diff. It provides regulated treatment through healthcare systems with defined dosing and safety monitoring. Unlike OpenBiome's foundation model, Ferring uses commercial pricing and distribution. It excels in late-stage clinical data but offers less emphasis on open grant funding or broad research infrastructure.
Free